Incorporation of 5-methylcytidine alleviates RIG-I-mediated innate immune responses to a self-amplifying RNA vaccine.
Saved in:
| Title: | Incorporation of 5-methylcytidine alleviates RIG-I-mediated innate immune responses to a self-amplifying RNA vaccine. |
|---|---|
| Authors: | Akahata W; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Komori M; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Morey AL; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Quiñones-Molina AA; Department of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA., Hood JB; Department of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA., Fofana J; Department of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA., Romero L; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Peters E; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Webber JD; HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Meeks T; HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Przygonska PA; HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Steinberg I; HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Ober E; HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Kim T; HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Rogan DC; HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Matsuda K; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Smith JF; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Gummuluru S; Department of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA., Connors M; HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA., Akiyama H; Department of Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA. |
| Source: | Science translational medicine [Sci Transl Med] 2025 Nov 12; Vol. 17 (824), pp. eadz2276. Date of Electronic Publication: 2025 Nov 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
